CIDARA THERAPEUTICS, INC. (NASDAQ:CDTX) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
was presented in an investor meeting by the management of Cidara
Therapeutics, Inc. (the Company). Information from this slide
presentation may also be used by the management of the Company in
future meetings regarding the Company.
of this Current Report on Form 8-K shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.
|
Item 9.01.
|
Financial Statements and Exhibits
|
About CIDARA THERAPEUTICS, INC. (NASDAQ:CDTX)
Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. CIDARA THERAPEUTICS, INC. (NASDAQ:CDTX) Recent Trading Information
CIDARA THERAPEUTICS, INC. (NASDAQ:CDTX) closed its last trading session down -0.20 at 7.25 with 136,062 shares trading hands.
